252 related articles for article (PubMed ID: 16391837)
1. Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity.
Ishizaki T; Katsumata K; Tsuchida A; Wada T; Mori Y; Hisada M; Kawakita H; Aoki T
Int J Mol Med; 2006 Feb; 17(2):357-62. PubMed ID: 16391837
[TBL] [Abstract][Full Text] [Related]
2. The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer.
Yamauchi T; Watanabe M; Hasegawa H; Nishibori H; Ishii Y; Tatematsu H; Yamamoto K; Kubota T; Kitajima M
Anticancer Res; 2003; 23(1A):245-9. PubMed ID: 12680220
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with selective cyclooxygenase-2 inhibitor and fluorinated pyrimidines for liver metastasis of colon cancer.
Matsunaga N; Yamada N; Ohira M; Tachimori A; Nishiguchi Y; Nishino H; Seki S; Hirakawa K
Oncol Rep; 2004 Jan; 11(1):167-71. PubMed ID: 14654921
[TBL] [Abstract][Full Text] [Related]
4. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
[TBL] [Abstract][Full Text] [Related]
5. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
[TBL] [Abstract][Full Text] [Related]
7. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
8. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
Hasegawa K; Ohashi Y; Ishikawa K; Yasue A; Kato R; Achiwa Y; Nishio E; Udagawa Y
Int J Oncol; 2005 May; 26(5):1419-28. PubMed ID: 15809736
[TBL] [Abstract][Full Text] [Related]
9. Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer.
Kahlert C; Bandapalli OR; Schirmacher P; Weitz J; Brand K
Anticancer Res; 2008; 28(3A):1459-65. PubMed ID: 18630499
[TBL] [Abstract][Full Text] [Related]
10. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of the gene expression of matrix metalloproteinase-7, insulin-like growth factor-1, insulin-like growth factor-2 and insulin-like growth factor-1 receptor in patients with colorectal cancer: insulin-like growth factor-1 receptor gene expression is a useful predictor of liver metastasis from colorectal cancer.
Oshima T; Akaike M; Yoshihara K; Shiozawa M; Yamamoto N; Sato T; Yamada R; Fujii S; Rino Y; Kunisaki C; Tanaka K; Masuda M; Imada T
Oncol Rep; 2008 Aug; 20(2):359-64. PubMed ID: 18636198
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells.
Ding HL; Guo Y; Xu MT; Li HY; Fu ZZ
Chin Med J (Engl); 2007 Nov; 120(21):1886-9. PubMed ID: 18067760
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
15. [Influence of recombinant transforming growth factor-beta3 on collagen synthesis and deposition: experiment with rat cell model of liver fibrosis].
Li Q; Zhou X; Yu J; Qian W; Xu KS
Zhonghua Yi Xue Za Zhi; 2008 May; 88(18):1273-8. PubMed ID: 18844103
[TBL] [Abstract][Full Text] [Related]
16. [Significance of MMP-9 and TIMP-1 production during liver metastasis in colorectal cancer].
Ogata Y; Ookita A; Kakegawa T
Nihon Rinsho; 1995 Jul; 53(7):1811-5. PubMed ID: 7630024
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis.
Iwata C; Kano MR; Komuro A; Oka M; Kiyono K; Johansson E; Morishita Y; Yashiro M; Hirakawa K; Kaminishi M; Miyazono K
Cancer Res; 2007 Nov; 67(21):10181-9. PubMed ID: 17974958
[TBL] [Abstract][Full Text] [Related]
18. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
[TBL] [Abstract][Full Text] [Related]
19. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
[TBL] [Abstract][Full Text] [Related]
20. Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer.
Lubbe WJ; Zhou ZY; Fu W; Zuzga D; Schulz S; Fridman R; Muschel RJ; Waldman SA; Pitari GM
Clin Cancer Res; 2006 Mar; 12(6):1876-82. PubMed ID: 16551873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
